Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.Obstetrics and gynecology
AbstractBACKGROUND: Intrauterine progesterone therapy has been proposed as a potential uterine-sparing treatment for atypical endometrial hyperplasia and adenocarcinoma. CASE: We present a case of an infertility patient with atypical endometrial hyperplasia who was treated with the levonorgestrel-releasing intrauterine system for 6 months. At follow-up, she was noted to have an increasing endometrial thickness on ultrasonography, and biopsy revealed progression of her lesion to adenocarcinoma. CONCLUSION: Although there is a need for uterine-sparing treatment for atypical endometrial hyperplasia and early adenocarcinoma, especially in the setting of desired fertility, caution should be exercised. We do not recommend using the levonorgestrel-releasing intrauterine system as a treatment for atypical hyperplasia or adenocarcinoma until further studies demonstrate the efficacy of this treatment.
- Contraceptive Agents,
- Endometrial Hyperplasia,
- Endometrial Neoplasms,
- Intrauterine Devices,
- Treatment Failure
Published Article/Book CitationObstetrics and gynecology (2008) 111:2 Pt 2, pp. 547-549.
Citation InformationJ. Kresowik, Ginny L. Ryan and Bradley J. Van Voorhis. "Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system." Obstetrics and gynecology Vol. 111 Iss. 2 Pt 2 (2008) p. 547 - 549 ISSN: 0029-7844
Available at: http://works.bepress.com/ginny_ryan/25/